Reply to B. Rini et al and S. Buti et al
J Clin Oncol
.
2017 Jun 1;35(16):1859-1860.
doi: 10.1200/JCO.2017.72.2629.
Epub 2017 Mar 6.
Authors
Toni K Choueiri
1
,
Susan Halabi
1
,
Michael J Morris
1
,
Daniel George
1
Affiliation
1
Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Susan Halabi, Duke University, Durham, NC; Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; and Daniel George, Duke University Medical Center, Durham, NC.
PMID:
28549224
DOI:
10.1200/JCO.2017.72.2629
No abstract available
Publication types
Letter
Comment
MeSH terms
Anilides
Carcinoma, Renal Cell*
Humans
Kidney Neoplasms*
Pyridines
Sunitinib
Substances
Anilides
Pyridines
cabozantinib
Sunitinib
Associated data
ClinicalTrials.gov/NCT01835158